This segment focuses on the research and development of oral biologic product candidates for the treatment of gastrointestinal (GI) diseases. The primary focus is on developing GI-selective therapeutics to address conditions like ulcerative colitis and other inflammatory bowel diseases. Research and development activities include the design and testing of novel drug delivery systems, such as the company's proprietary technology platform. Technologies employed include protein engineering, formulation science, and advanced analytical techniques to ensure drug efficacy and safety. The segment's lead product candidate, AMT-101, is in Phase II clinical trials for ulcerative colitis. The patient impact is significant, as these therapies aim to reduce inflammation, improve symptoms, and potentially induce remission in patients with debilitating GI conditions. Market positioning involves targeting unmet medical needs in the GI therapeutic space, with a focus on oral delivery to improve patient convenience and compliance. Future opportunities include expanding the pipeline to address other GI disorders and exploring partnerships to accelerate clinical development and commercialization. Regulatory and clinical aspects involve navigating the FDA approval process and conducting rigorous clinical trials to demonstrate safety and efficacy. Collaborations may include partnerships with academic institutions and other pharmaceutical companies to leverage expertise and resources.

This segment is dedicated to the development of therapeutics aimed at addressing defects in intestinal epithelium barrier function. The research and development efforts center around creating oral biologic product candidates that can restore and enhance the integrity of the intestinal barrier. This involves utilizing the company's technology platform to design and develop novel therapeutic modalities, including peptides, proteins, and antibody fragments. The segment's focus is on diseases related to intestinal epithelium barrier function defects. The technologies used include protein engineering, formulation science, and advanced analytical techniques. The patient impact is aimed at improving the quality of life for patients suffering from conditions related to intestinal barrier dysfunction. Market positioning involves targeting unmet medical needs in the GI therapeutic space, with a focus on oral delivery to improve patient convenience and compliance. Future opportunities include expanding the pipeline to address other GI disorders and exploring partnerships to accelerate clinical development and commercialization. Regulatory and clinical aspects involve navigating the FDA approval process and conducting rigorous clinical trials to demonstrate safety and efficacy. Collaborations may include partnerships with academic institutions and other pharmaceutical companies to leverage expertise and resources.